西南证券发布伟思医疗研报：2025H1业绩符合预期，盈利能力有所提升

Group 1 - The core viewpoint of the report indicates that Weisi Medical (688580.SH) is expected to see a steady recovery in performance in the first half of 2025, with promising results from emerging businesses [1] - The report highlights rapid growth in laser radiofrequency and electrophysiology products, while the magnetic stimulation business is facing short-term pressure [1] - The core product matrix of the company continues to expand, with new emerging pipelines showing significant potential [1]